News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay
Raffaele Colombo/LinkedIn
May 4, 2025, 03:18

Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X by Stephen V Liu, adding:

“Based on AstraZeneca’s QCS for TROP2,
Roche Diagnostics received FDA Breakthrough Device Designation (BDD) for the VENTANA TROP2 (EPR20043) RxDx assay!
Nice spotlight presentation at AACR25.”

Read more about Roche’s FDA Breakthrough Device Designation for AI-driven NSCLC diagnostic here.

Raffaele Colombo

Quoting Stephen V Liu‘s post:

“Dr. Marina Garassino at WCLC24 Presidential Plenary presents Normalized Membrane Ratio of TROP2 as a biomarker for datopotamab deruxtecan in TROPION-Lung01 (Dato-DXd vs docetaxel in previously treated NSCLC which previously showed PFS benefit with Dato-DXd.“

Stephen V Liu

Learn more about Raffaele Colombo and TROPION-Lung01 on OncoDaily. 

AACR AACR25 AstraZeneca Breakthrough Device Designation cancer Dato-DXd datopotamab deruxtecan FDA Marina Garassino Medicine at Georgetown University NSCLC OncoDaily Oncology Roche Diagnostics Stephen V Liu TROP2 TROPION-Lung01 VENTANA TROP2 WCLC24 Zymeworks
Special Coverage
Insight
May 4, 2025, 03:18
Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay
Blog
May 4, 2025, 03:11
Digestive Cancers Europe: Download My DiCE Companion to monitor your cancer journey
Career
May 4, 2025, 02:53
Narjust Florez: Why run for the IASLC?
Opinion
May 4, 2025, 02:40
Abner Antonio Murray highlights Brooke Felsheim and Charles Perou’s key findings at AACR25 on TNBC prognosis
Insight
May 4, 2025, 02:34
Oscar Tahuahua: Rational combos and next-gen RAS inhibitors are key
Blog
May 4, 2025, 02:20
Lisa Craine presented poster on mentorship and social media in cholangiocarcinoma journey at AACR 2025
Blog
May 4, 2025, 02:03
Greisha Lee Ortíz-Hernández: I am honored to belong to a scientific community that thrives and lifts each other up
Blog
May 4, 2025, 01:51
AACR25 Clinical Trials plenary highlights advances in expanding Immunotherapy access
Blog
May 4, 2025, 01:46
Maryam Lustberg: Chroninc neuropathy is a toxicity that we need to help mitigate in every way possible
Blog
May 4, 2025, 01:38
Lauren Henke highlights NRG Oncology Podcast on pancreatic cancer research and RTOG 0848
Blog
May 4, 2025, 01:29
Aparna Parikh: Excited to be a part of Parithera's team
Blog
May 4, 2025, 01:19
Gregg Margolis: Key health policy reads of the week